Top

Published in:

07-03-2024 | Alzheimer's Disease | REVIEWS

The Role of the Serotonin Pathway of Tryptophan Metabolism in the Development of Neuroinflammation in Alzheimer’s Disease

Authors: A. S. Fomin, S. P. Sergeeva

Published in: Advances in Gerontology | Issue 3/2023

Abstract

Despite the fact that more than 90% of tryptophan is metabolized via the kynurenine pathway, the serotonin pathway is of great importance for the functioning of the central nervous system. The main products of this pathway are serotonin and melatonin. They provide maintenance of the sleep–wake mode, modulation of oxidative stress activity, apoptosis of neurons and glial elements, regeneration and neuroinflammation. In the pathogenesis of Alzheimer’s disease, neuroinflammation plays one of the main roles. Melatonin and serotonin, being modulators of its intensity, as well as an important component of neurochemical interactions that provide cognitive functions, can be considered as targets for preventive and therapeutic effects.

Abg Abd Wahab, D.Y., Gau, C.H., Zakaria, R., Muthu Karuppan, M.K., A-Rahbi, B.S., Abdullah, Z., Alrafiah, A., Abdullah, J.M., and Muthuraju, S., Review on cross talk between neurotransmitters and neuroinflammation in striatum and cerebellum in the mediation of motor behaviour, Biomed. Res. Int., 2019, vol. 2019, p. 1767203. PMID: 31815123; PMCID: PMC6877979. https://doi.org/10.1155/2019/1767203CrossRefPubMedPubMedCentral

Agüero, P., Sainz, M.J., García-Ayllón, M.S., Sáez-Valero, J., Téllez, R., Guerrero-López, R., Pérez-Pérez, J., Jimenéz-Escrig, A., and Gómez-Tortosa, E., α‑Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer’s disease, Alzheimers Res. Ther., 2020, vol. 12, no. 1, p. 139. PMID: 33129344; PMCID: PMC7603780. https://doi.org/10.1186/s13195-020-00708-0CrossRefPubMedPubMedCentral

Alghamdi, B.S., The neuroprotective role of melatonin in neurological disorders, J. Neurosci. Res., 2018, vol. 96, no. 7, pp. 1136–1149. PMID: 29498103; PMCID: PMC6001545. https://doi.org/10.1002/jnr.24220CrossRefPubMedPubMedCentral

Anderson, G., Depression pathophysiology: Astrocyte mitochondrial melatonergic pathway as crucial hub, Int. J. Mol. Sci., 2022, vol. 24, no. 1, p. 350. PMID: 36613794; PMCID: PMC9820523. https://doi.org/10.3390/ijms24010350CrossRefPubMedPubMedCentral

Andrews, P.W., Bosyj, C., Brenton, L., Green, L., Gasser, P.J., Lowry, C.A., and Pickel, V.M., All the brain’s a stage for serotonin: The forgotten story of serotonin diffusion across cell membranes, Proc. Biol. Sci., 2022, vol. 289, no. 1986, p. 20221565. PMID: 36321487; PMCID: PMC9627707. https://doi.org/10.1098/rspb.2022.1565

Chakraborty, S., Lennon, J.C., Malkaram, S.A., Zeng, Y., Fisher, D.W., and Dong, H., Serotonergic system, cognition, and BPSD in Alzheimer’s disease, Neurosci. Lett., 2019, vol. 704, pp. 36–44.https://doi.org/10.1016/j.neulet.2019.03.050

Chen, D., Zhang, T., and Lee, T.H., Cellular mechanisms of melatonin: Insight from neurodegenerative diseases, Biomolecules, 2020, vol. 10, no. 8, p. 1158. PMID: 32784556; PMCID: PMC7464852. https://doi.org/10.3390/biom10081158CrossRefPubMedPubMedCentral

Correia, A.S. and Vale, N., Tryptophan metabolism in depression: A narrative review with a focus on serotonin and kynurenine pathways, Int. J. Mol. Sci., 2022, vol. 23, no. 15, p. 8493. PMID: 35955633; PMCID: PMC9369076. https://doi.org/10.3390/ijms23158493CrossRefPubMedPubMedCentral

Fakhoury, M., Microglia and astrocytes in Alzheimer’s disease: Implications for therapy, Curr. Neuropharmacol., 2018, vol. 16, no. 5, pp. 508–518. PMID: 28730967; PMCID: PMC5997862. https://doi.org/10.2174/1570159X15666170720095240CrossRefPubMedPubMedCentral

10.

Fan, R., Peng, X., Xie, L., Dong, K., Ma, D., Xu, W., Shi, X., Zhang, S., Chen, J., Yu, X., and Yang, Y., Importance of Bmal1 in Alzheimer’s disease and associated aging-related diseases: Mechanisms and interventions, Aging Cell, 2022, vol. 21, no. 10, p. e13704. PMID: 36056774; PMCID: PMC9577946. https://doi.org/10.1111/acel.13704CrossRefPubMedPubMedCentral

11.

Fanet, H., Capuron, L., Castanon, N., Calon, F., and Vancassel, S., Tetrahydrobioterin (BH4) pathway: From metabolism to neuropsychiatry, Curr. Neuropharmacol., 2021, vol. 19, no. 5, pp. 591–609. PMID: 32744952; PMCID: PMC8573752. https://doi.org/10.2174/1570159X18666200729103529

12.

Gao, K., Mu, C.L., Farzi, A., and Zhu, W.Y., Tryptophan metabolism: A link between the gut microbiota and brain, Adv. Nutr., 2020, vol. 11, no. 3, pp. 709–723. PMID: 31825083; PMCID: PMC7231603. https://doi.org/10.1093/advances/nmz127CrossRefPubMed

13.

Grifka-Walk, H.M., Jenkins, B.R., and Kominsky, D.J., Amino acid Trp: The far out impacts of host and commensal tryptophan metabolism, Front. Immunol., 2021, vol. 12, p. 653208. PMID: 34149693; PMCID: PMC8213022. https://doi.org/10.3389/fimmu.2021.653208CrossRefPubMedPubMedCentral

14.

Homolak, J., Mudrovčić, M., Vukić, B., Toljan, K., Circadian, rhythm and Alzheimer’s disease, Med. Sci. (Basel), 2018, vol. 6, no. 3, p. 52. PMID: 29933646; PMCID: PMC6164904. https://doi.org/10.3390/medsci6030052CrossRefPubMed

15.

Jayamohananan, H., Manoj Kumar, M.K., and Aneesh, T.P., 5-HIAA as a potential biological marker for neurological and psychiatric disorders, Adv. Pharm. Bull., 2019, vol. 9, no. 3, pp. 374–381. PMID: 31592064; PMCID: PMC6773935. https://doi.org/10.15171/apb.2019.044CrossRefPubMedPubMedCentral

16.

Khan, S., Barve, K.H., and Kumar, M.S., Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer’s disease, Curr. Neuropharmacol., 2020, vol. 18, no. 11, pp. 1106–1125. PMID: 32484110; PMCID: PMC7709159. https://doi.org/10.2174/1570159X18666200528142429

17.

Lee, B.H., Hille, B., and Koh, D.S., Serotonin modulates melatonin synthesis as an autocrine neurotransmitter in the pineal gland, Proc. Natl. Acad. Sci. U.S.A., 2021, vol. 118, no. 43, p. e2113852118. PMID: 34675083; PMCID: PMC8639368. https://doi.org/10.1073/pnas.2113852118CrossRefPubMedPubMedCentral

18.

Li, D., Yu, S., Long, Y., Shi, A., Deng, J., Ma, Y., Wen, J., Li, X., Liu, S., Zhang, Y., Wan, J., Li, N., and Ao, R., Tryptophan metabolism: Mechanism-oriented therapy for neurological and psychiatric disorders, Front. Immunol., 2022, vol. 13, p. 985378. PMID: 36159806; PMCID: PMC9496178. https://doi.org/10.3389/fimmu.2022.985378CrossRefPubMedPubMedCentral

19.

Li, Y., Zhang, J., Wan, J., Liu, A., and Sun, J., Melatonin regulates Aβ production/clearance balance and Aβ neurotoxicity: A potential therapeutic molecule for Alzheimer’s disease, Biomed. Pharmacother., 2020, vol. 132, p. 110887. PMID: 33254429. https://doi.org/10.1016/j.biopha.2020.110887CrossRefPubMed

20.

Luo, F., Sandhu, A.F., Rungratanawanich, W., Williams, G.E., Akbar, M., Zhou, S., Song, B.J., and Wang, X., Melatonin and autophagy in aging-related neurodegenerative diseases, Int. J. Mol. Sci., 2020, vol. 21, no. 19, p. 7174. PMID: 32998479; PMCID: PMC7584015. https://doi.org/10.3390/ijms21197174CrossRefPubMedPubMedCentral

21.

Ma, C., Hong, F., and Yang, S., Amyloidosis in Alzheimer’s disease: Pathogeny, etiology, and related therapeutic directions, Molecules, 2022, vol. 27, no. 4, p. 1210. PMID: 35209007; PMCID: PMC8876037. https://doi.org/10.3390/molecules27041210CrossRefPubMedPubMedCentral

22.

Melhuish Beaupre, L.M., Brown, G.M., Gonçalves, V.F., and Kennedy, J.L., Melatonin’s neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders, Transl. Psychiatry, 2021, vol. 11, no. 1, p. 339. PMID: 34078880; PMCID: PMC8172874. https://doi.org/10.1038/s41398-021-01464-xCrossRefPubMedPubMedCentral

23.

Modoux, M., Rolhion, N., Mani, S., and Sokol, H., Tryptophan metabolism as a pharmacological target, Trends Pharmacol. Sci., 2021, vol. 42, no. 1, pp. 60–73. PMID: 33256987. https://doi.org/10.1016/j.tips.2020.11.006CrossRefPubMed

24.

Nikolaev, G., Robeva, R., and Konakchieva, R., Membrane melatonin receptors activated cell signaling in physiology and disease, Int. J. Mol. Sci., 2021, vol. 23, no. 1, p. 471. PMID: 35008896; PMCID: PMC8745360.https://doi.org/10.3390/ijms23010471CrossRefPubMedPubMedCentral

25.

Petrus, P., Cervantes, M., Samad, M., et al., Tryptophan metabolism is a physiological integrator regulating circadian rhythms, Mol. Metab., 2022, vol. 64, p. 101556. PMID: 35914650; PMCID: PMC9382333. https://doi.org/10.1016/j.molmet.2022.101556

26.

Sabir, M.S., Haussler, M.R., Mallick, S., Kaneko, I., Lucas, D.A., Haussler, C.A., Whitfield, G.K., and Jurutka, P.W., Optimal vitamin D spurs serotonin: 1,25-dihydroxyvitamin D represses serotonin reuptake transport (SERT) and degradation (MAO-A) gene expression in cultured rat serotonergic neuronal cell lines, Genes Nutr., 2018, vol. 13, p. 19. PMID: 30008960; PMCID: PMC6042449. https://doi.org/10.1186/s12263-018-0605-7CrossRefPubMedPubMedCentral

27.

Sacramento, P.M., Monteiro, C., Dias, A.S.O., Kasahara, T.M., Ferreira, T.B., Hygino, J., Wing, A.C., Andrade, R.M., Rueda, F., Sales, M.C., Vasconcelos, C.C., and Bento, C.A.M., Serotonin decreases the production of Th1/Th17 cytokines and elevates the frequency of regulatory CD4⁺ T-cell subsets in multiple sclerosis patients, Eur. J. Immunol., 2018, vol. 48, no. 8, pp. 1376–1388. PMID: 29719048. https://doi.org/10.1002/eji.201847525CrossRefPubMed

28.

Savonije, K. and Weaver, D.F., The role of tryptophan metabolism in Alzheimer’s disease, Brain Sci., 2023, vol. 13, no. 2, p. 292. PMID: 36831835; PMCID: PMC9954102. https://doi.org/10.3390/brainsci13020292CrossRefPubMedPubMedCentral

29.

Scotton, W.J., Hill, L.J., Williams, A.C., and Barnes, N.M., Serotonin syndrome: Pathophysiology, clinical features, management, and potential future directions, Int. J. Tryptophan Res., 2019, vol. 12, p. 1178646919873925. PMID: 31523132; PMCID: PMC6734608. https://doi.org/10.1177/1178646919873925CrossRefPubMedPubMedCentral

30.

Singh, A., Ansari, V.A., Mahmood, T., Ahsan, F., and Wasim, R., Neurodegeneration: Microglia: Nf-Kappab signaling pathways, Drug Res., 2022, vol. 72, no. 9, pp. 496–499. PMID: 36055286. https://doi.org/10.1055/a-1915-4861CrossRef

31.

Song, J., Pineal gland dysfunction in Alzheimer’s disease: Relationship with the immune–pineal axis, sleep disturbance, and neurogenesis, Mol. Neurodegener., 2019, vol. 14, no. 1, p. 28. PMID: 31296240; PMCID: PMC6624939. https://doi.org/10.1186/s13024-019-0330-8CrossRefPubMedPubMedCentral

32.

Wan, M., Ding, L., Wang, D., Han, J., and Gao, P., Serotonin: A potent immune cell modulator in autoimmune diseases, Front. Immunol., 2020, vol. 11, p. 186. PMID: 32117308; PMCID: PMC7026253. https://doi.org/10.3389/fimmu.2020.00186CrossRefPubMedPubMedCentral

33.

Winn, S.R., Scherer, T., Thöny, B., Ying, M., Martinez, A., Weber, S., Raber, J., and Harding, C.O., Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice, Mol. Genet. Metab., 2018, vol. 123, no. 1, p. 6–20. PMID: 29331172; PMCID: PMC5786171. https://doi.org/10.1016/j.ymgme.2017.10.009CrossRefPubMed

34.

Kozin, S.A. and Makarov, A.A., The convergence of Alzheimer’s disease pathogenesis concepts, Mol. Biol. (Moscow), 2019, vol. 53, no. 6, pp. 1020–1028. PMID: 31876280. https://doi.org/10.1134/S0026898419060107CrossRefPubMed

35.

Garbuz, D.G., Zatsepina, O.G., and Evgen’ev, M.B., Beta amyloid, tau protein, and neuroinflammation: An attempt to integrate different hypotheses of Alzheimer’s disease pathogenesis, Mol. Biol. (Moscow), 2021, vol. 55, no. 5, pp. 734–747. PMID: 34671002. https://doi.org/10.31857/S0026898421050049CrossRefPubMed

36.

Gogoleva, V.S., Drutskaya, M.S., and Atretkhany, K.S., The role of microglia in the homeostasis of the central nervous system and neuroinflammation, Mol. Biol. (Moscow), 2019, vol. 53, no. 5, pp. 790–798. PMID: 31661478.https://doi.org/10.1134/S0026898419050057CrossRefPubMed

Title: The Role of the Serotonin Pathway of Tryptophan Metabolism in the Development of Neuroinflammation in Alzheimer’s Disease
Authors: A. S. Fomin
S. P. Sergeeva
Publication date: 07-03-2024
Publisher: Pleiades Publishing
Keywords: Alzheimer's Disease
Alzheimer's Disease
Published in: Advances in Gerontology / Issue 3/2023
Print ISSN: 2079-0570
Electronic ISSN: 2079-0589
DOI: https://doi.org/10.1134/S207905702460023X

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2023

Age-Related Changes and Loss of Damage Resistance of Kidney Tissue: The Role of a Decrease in the Number of Kidney Resident Progenitor Cells

Mechanisms of Neurocognitive Adaptation during Aging Process

The Role of Kynurenine Pathway Metabolites in the Development of Frailty in Older Adults

The Rate of Aging and Its Association with Risk Factors of Cardiovascular Diseases

Vascular Aging and Telomere Biology: On the Role of Vitamin D3 Deficiency

Demographic Indicators of Probability Models

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials